DLP
NEPH icon

De Lisle Partners’s Nephros NEPH Stock Holding History

De Lisle Partners’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.5K Hold
25,000
– – 0.01% 173
2025
Q4 		$122K Buy
+25,000
New +$128K 0.02% 169

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Cornerstone Capital Palo Alto, California $1B AUM 21.47% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

De Lisle Partners's NEPH Position: Q1 2026 in Review

De Lisle Partners held its Nephros (NEPH) position steady in Q1 2026 at 25,000 shares worth $74.5K. The position accounts for 0.01% of the portfolio, ranked #173.

De Lisle Partners first reported a position in NEPH in Q4 2025 and has held it in 2 quarters since. The position peaked at $122K in Q4 2025. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

  • De Lisle Partners held 25,000 shares of Nephros worth $74.5K as of Q1 2026.
  • De Lisle Partners left its Nephros share count unchanged in Q1 2026.
  • Nephros made up 0.01% of De Lisle Partners's portfolio in Q1 2026, its #173 holding.
  • De Lisle Partners first reported a position in Nephros in Q4 2025 and has held it in 2 quarters since.
  • De Lisle Partners's Nephros position peaked at $122K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on De Lisle Partners's 13F filing for Q1 2026, filed 13 May 2026.